XNASTHRD
Market cap255mUSD
Jan 16, Last price
5.68USD
1D
-5.33%
1Q
-57.80%
IPO
-68.44%
Name
Third Harmonic Bio Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-31m
L-18.26%
CFO
-20m
L-41.50%
Dividend
Aug 06, 20140.12 USD/sh
Profile
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 43,989 | 37,746 | ||
Unusual Expense (Income) | ||||
NOPBT | (43,989) | (37,746) | ||
NOPBT Margin | ||||
Operating Taxes | 2,553 | |||
Tax Rate | ||||
NOPAT | (43,989) | (40,299) | ||
Net income | (30,824) -18.26% | (37,708) 27.35% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 799 | 198,178 | ||
BB yield | -0.18% | -117.04% | ||
| Debt | ||||
Debt current | 1,490 | 385 | ||
Long-term debt | 7,161 | 8,293 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (260,419) | (280,640) | ||
| Cash flow | ||||
Cash from operating activities | (20,425) | (34,917) | ||
CAPEX | (169) | (36) | ||
Cash from investing activities | (169) | (36) | ||
Cash from financing activities | 799 | 195,991 | ||
FCF | (43,559) | (44,661) | ||
| Balance | ||||
Cash | 269,070 | 288,877 | ||
Long term investments | 441 | |||
Excess cash | 269,070 | 289,318 | ||
Stockholders' equity | (114,216) | 215,283 | ||
Invested Capital | 387,999 | 78,124 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 39,645 | 39,377 | ||
Price | 10.97 155.12% | 4.30 | ||
Market cap | 434,910 156.85% | 169,322 | ||
EV | 174,491 | 187,357 | ||
EBITDA | (43,954) | (37,745) | ||
EV/EBITDA | ||||
Interest | 2,553 | |||
Interest/NOPBT | ||||